SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-308473
Filing Date
2020-12-02
Accepted
2020-12-02 16:59:55
Documents
19
Period of Report
2020-12-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d26796d8k.htm   iXBRL 8-K 33732
2 EX-1.1 d26796dex11.htm EX-1.1 163624
3 EX-5.1 d26796dex51.htm EX-5.1 5726
4 EX-99.1 d26796dex991.htm EX-99.1 10175
5 EX-99.2 d26796dex992.htm EX-99.2 10418
9 GRAPHIC g26796dsp41.jpg GRAPHIC 4327
10 GRAPHIC g26796dsp41a.jpg GRAPHIC 8082
11 GRAPHIC g26796dsp41b.jpg GRAPHIC 1906
  Complete submission text file 0001193125-20-308473.txt   424903

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ntla-20201201.xsd EX-101.SCH 3063
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20201201_lab.xml EX-101.LAB 18138
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20201201_pre.xml EX-101.PRE 11403
12 EXTRACTED XBRL INSTANCE DOCUMENT d26796d8k_htm.xml XML 3350
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 201364488
SIC: 2835 In Vitro & In Vivo Diagnostic Substances